Cyclana Bio

Executive Summary

Cyclana Bio is a UK-based biotechnology company founded in 2021, dedicated to transforming women's health by developing novel treatments for conditions like endometriosis. The company's innovative approach leverages menstrual fluid—a unique and underutilized biological resource—to build physiological disease models and identify new therapeutic targets. By focusing on tissue and extracellular matrix biology, Cyclana aims to address the significant gender health gap, which has historically left women's health conditions under-researched and under-treated. The company's platform has the potential to unlock deep scientific insights into endometriosis and other reproductive disorders, paving the way for impactful therapies. While still in early stages, Cyclana's differentiated strategy and focus on a large unmet need position it as a compelling player in the rare disease and metabolic spaces. However, the company has not disclosed funding details or valuation, and its pipeline is yet to be publicly defined. The success of Cyclana will depend on its ability to secure funding, validate its platform through preclinical studies, and advance toward clinical development.

Upcoming Catalysts (preview)

• TBDSeries A Funding Announcement60% success
• TBDPreclinical Proof-of-Concept Data for Endometriosis Lead Candidate50% success
• TBDAcademic or Industry Partnership for Platform Validation70% success